mdlinx mdlinx

Oncology - Renal/Urologic News & Articles

Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.

On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx
New! >> Find out who is the Smartest Doc in Oncology!

Articles

Latest (7) Full Text Articles (529) Focus on Urology
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

1 Relationship of gleason patterns in gleason score 7 prostate cancer Cancer Research, May 24, 2013    Clinical Article

2 ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kB and drives prostate cancer progression. Cancer Research, May 24, 2013    Clinical Article

3 The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients British Journal of Cancer, May 24, 2013    Clinical Article

4 Recent advances in the treatment of metastatic renal cell carcinoma International Journal of Urology, May 24, 2013    Clinical Article

5 Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml International Journal of Clinical Practice, May 24, 2013    Clinical Article

6 A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACAG) in patients with locally advanced carcinoma of the bladder Urology, May 24, 2013    Clinical Article

7 Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era Urology, May 24, 2013    Clinical Article

Prior Articles

8 Diabetes mellitus and prostate cancer risk Cancer Epidemiology, Biomarkers & Prevention, May 23, 2013

9 Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma British Journal of Cancer, May 23, 2013

10 Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer British Journal of Cancer, May 23, 2013

11 Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort European Journal of Cancer, May 23, 2013

12 Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma Acta Oncologica, May 23, 2013    Clinical Article

13 Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis Clinical Therapeutics, May 23, 2013    Clinical Article

14 Expression and biological roles of SATB1 in human bladder cancer Tumor Biology, May 23, 2013    Clinical Article

15 Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study The Lancet Oncology, May 23, 2013    Clinical Article

16 Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the international mRCC database consortium criteria Cancer, May 23, 2013    Review Article

17 Using the epigenetic field defect to detect prostate cancer in biopsy negative patients The Journal of Urology, May 23, 2013    Clinical Article

18 Causes of death in men with prostate cancer: an analysis of 50,000 men from the thames cancer registry BJU International, May 23, 2013    Clinical Article

19 Clinical performance of serum isoform [-2]propsa (p2psa) and its derivatives, namely %p2psa and phi (prostate health index), in men with a family history of prostate cancer. Results from a multicentre European study (prometheus project) BJU International, May 23, 2013    Clinical Article

20 Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma International Urology and Nephrology, May 23, 2013    Review Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 Next Last

Clinical Pearls in Oncology

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.

Read the article summary

HCC risk increased in patients with AIDS

As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.

Read the article summary

RAB25 is a prognostic marker for ovarian cancer

As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

1 Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Annals of Oncology, April 19, 2013

2 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013

3 Gene-Environment Interactions in Bladder Cancer Cancer Research, April 1, 2013

4 Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer Annual Review of Medicine, April 26, 2013    Review Article

5 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013

6 The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies World Journal of Urology, April 2, 2013    Review Article

7 Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer Current Opinion in Oncology, April 10, 2013    Review Article

8 Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma Urologic Oncology: Seminars and Original Investigations, April 1, 2013

9 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, April 24, 2013

10 Advances in bladder cancer imaging BMC Medicine, April 15, 2013    Free full text    Review Article

11 Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer Cancer Causes and Control, April 8, 2013

12 Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort European Journal of Cancer, March 22, 2013

13 Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer Journal of the National Cancer Institute, April 11, 2013

14 Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria British Journal of Haematology, April 26, 2013

15 Low serum testosterone levels are predictive of prostate cancer World Journal of Urology, April 9, 2013

16 Aberrant BAF57 Signaling Facilitates Pro-metastatic Phenotypes Clinical Cancer Research, April 1, 2013

17 Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology, March 25, 2013

18 Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09) The Lancet Oncology, March 7, 2013

19 Urothelial carcinoma of the bladder and the upper tract: disparate twins The Journal of Urology, April 18, 2013    Review Article

20 A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer Annals of Oncology, April 19, 2013

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close